Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.
Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a PARP inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to findings from 2 clinical trials presented at the 2017 ASCO annual meeting.
Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.
Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.
CDK4/CDK6 inhibitors will most likely not have a role as monotherapy, said Ingrid Mayer, MD, Associate Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, who discussed the study results.
Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults.
According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab.
Peripheral neuropathy is the result of damage to the peripheral nervous system, the complex network of nerves that transmits messages between the brain and other parts of the body. Such damage can cause impaired movement, loss of sensation in the arms and legs, numbness, tingling, and pain.